Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bumetanide for focal muscle weakness attacks in hypokalaemic periodic paralysis (McManis protocol)
2013-004195-36Phase 2Terminated
- Sponsor
- University College London
- Start
- Jun 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of bumetanide in hypokalemic periodic paralysis (HypoPP) and familial periodic paralysis (PP) (2 arms), sponsored by University College London. Primary endpoint: Focal attack severity at 1 hour after treatment. Started Jun 2014; status: terminated.
02
Drugs
bumetanide
03
Conditions
hypokalemic periodic paralysis (HypoPP)familial periodic paralysis (PP)
Beyond the preview
Go deeper on 2013-004195-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004195-36.